Merck & Co. Inc. (MRK): One of the Best Low Risk High Growth Stocks to Buy Right Now

We just covered the 14 Best Low Risk High Growth Stocks to Buy Right Now and Merck & Co., Inc. (NYSE:MRK) ranks 6th on this list.

It is no secret that the pharmaceutical industry is facing a super-cliff of patent expirations, Merck & Co., Inc. (NYSE:MRK) has successfully de-risked its future by diversifying its oncology portfolio and scaling its multi-billion dollar cardiovascular and vaccine franchises. Elite investors are treating the stock as a growth play due to the launch of Winrevair. Recently released data from the CADENCE trial provided definitive proof-of-concept for Winrevair in treating heart failure with preserved ejection fraction. Analysts predict this drug could capture 2-3 times its original market target, turning it into a $5 billion+ annual revenue powerhouse by 2028. This success is vital because it provides high-margin growth that is entirely independent of Merck’s flagship drug, Keytruda.

Citigroup Inc. (C): Among Incredibly Cheap Dividend Stock to Buy Now

Merck & Co., Inc. (NYSE:MRK) continues to report double-digit international growth for its HPV vaccine, Gardasil. New long-term efficacy data presented at the EUROGIN 2026 Congress reinforced its status as a non-optional global health utility. Earlier this month, the European Commission approved ENFLONSIA for RSV prevention in infants, positioning Merck to capture a significant share of the multi-billion dollar RSV immunization market. The firm maintains a massive cash flow and a low Beta of 0.26. It is a favorite for income-focused funds, currently trading with a forward P/E of roughly 20x.

READ NEXTIsrael Englander Stock Portfolio: Top 10 Stock Picks and Billionaire Stan Druckenmiller’s 10 Small and Mid-Cap Stock Picks with Huge Upside Potential.

Disclosure: None. Follow Insider Monkey on Google News.